Company Overview
BiomX Inc. operates as a clinical-stage biopharmaceutical entity focused on the development of phage-based therapies that utilize natural and engineered bacteriophage technologies to target and eliminate specific harmful bacteria linked to chronic diseases. The company functions within the healthcare sector, specifically the biotechnology industry, a landscape characterized by high research and development expenditures and the pursuit of novel therapeutic modalities to address unmet medical needs. As of the latest reporting period, BiomX Inc. holds a market capitalization of $7.36M and employs approximately 20 individuals dedicated to its scientific and operational objectives. The combination of a market cap under $10 million and an absence of reported annual revenue indicates that the company is in an early-stage development phase where capital allocation is heavily weighted toward advancing clinical programs rather than generating commercial income. This small market valuation relative to the biotechnology industry suggests the firm is positioning itself for potential future expansion upon the successful progression of its fixed cocktail therapy and other investigational products.
Financial Health
The financial performance metrics for BiomX Inc. reveal a significant loss position, with a net income (TTM) of $-36,199,000 and an EBITDA of $-27,998,000, while reported revenue is listed as N/A. The substantial gap between the reported revenue figures and the massive net losses underscores a cost structure driven entirely by operating expenses associated with research, development, and clinical trial activities, as the company has not yet achieved commercial profitability. Free cash flow stands at $-14,071,500, indicating that the company's current financial flexibility is constrained by ongoing burn rates that must be covered by existing cash reserves or external financing. All three margin metrics—gross margin, operating margin, and profit margin—are reported as 0.0%, which reflects the current state of operations where revenue is insufficient to cover the direct costs of goods sold and operating expenses, resulting in zero positive contribution from these traditional profitability measures. The balance sheet shows a cash position of $4.36M against total debt of $1.44M, suggesting a net cash position, although the debt-to-equity ratio is listed as N/A due to the absence of equity value in the denominator for this calculation. The current ratio is 0.87, which indicates that the company's current assets are insufficient to cover its current liabilities without relying on external funding or asset liquidation in the short term. Return on Equity is -316.9% and Return on Assets is -78.9%, metrics that reveal management is currently utilizing shareholder capital and company assets to generate significant losses rather than returns, a typical characteristic of clinical-stage companies prior to product approval.
Valuation Assessment
Valuation multiples for BiomX Inc. present a unique picture given the company's lack of profitability, with a P/E Ratio (TTM) of N/A and a Forward P/E of -0.36. The negative forward P/E ratio implies that the market is pricing in future earnings expectations that are currently negative, reflecting the high-risk nature of investing in a pre-revenue biotechnology firm. The price-to-book ratio is -0.37, a figure that indicates the stock is trading below its book value and suggests the market is not assigning a premium to the company's tangible assets, which is consistent with a firm whose value is derived from intangible intellectual property and clinical pipeline potential. Alternative valuation metrics such as the price-to-sales ratio, listed as N/A, and the EV/EBITDA of -0.82, further highlight the limitations of standard valuation models for this asset class where traditional earnings and sales data are not yet generated. The 52-week trading range spans from a low of $1.50 to a high of $14.71, providing a wide band within which the current price fluctuates based on market sentiment regarding clinical trial outcomes. The beta value of 1.70 indicates that the stock's price volatility is significantly higher than the broader market, moving 70% more volatile than the benchmark index, which amplifies both potential gains and losses for holders.
Growth & Income
Growth metrics for BiomX Inc. are reported as N/A for both revenue growth year-over-year and earnings growth year-over-year, reflecting the company's current stage where commercial sales have not yet commenced to generate comparable growth rates. Since the company is not a dividend payer, there is no dividend yield or payout ratio to analyze, meaning the firm does not distribute cash to shareholders but instead retains all earnings to fund operations and development. In the absence of dividend payouts, the company reinvests its limited cash resources and any future earnings directly into its clinical-stage pipeline to advance phage-based therapies toward market approval. The overall growth and income profile for BiomX Inc. is defined entirely by its potential for future expansion rather than current income generation, as the financial data confirms a reliance on external capital to sustain operations until the development of its therapeutic products yields commercial returns.